Malignancy in Relation to Autoimmune Blistering Dermatoses: Molecular and Clinical Aspects by Pietkiewicz, Paweł et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Malignancy in Relation to Autoimmune Blistering
Dermatoses: Molecular and Clinical Aspects
Paweł Pietkiewicz, Justyna Gornowicz-Porowska,
Monika Bowszyc-Dmochowska and
Marian Dmochowski
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/55240
1. Introduction
Autoimmune blistering dermatoses (ABD) are a group of relatively rare autoantibody-driven
diseases affecting primarily skin and/or multiple mucosa. They comprise of two main subdi‐
visions: ABD with autoimmunity to enzymes (dermatitis herpetiformis only) and ABD with
autoimmunity to mostly structural proteins (anti-desmosomal autoimmunity circle, anti-
dermal-epidermal junction autoimmunity circle and others). As both coexistent development
of organ specific autoimmunity (e.g. myasthenia gravis) and transition between ABD groups
are possible, ABD seem to be a part of pathological multiorgan autoimmunization syndrome
[1]. The replacement of physiological autoimmunity by pathological autoimmunity and
triggering blister formation in ABD still remain unexplored and essential issues. It is suggested
that malignancy may be a triggering factor inducing the development of pathological auto‐
immunity. On the other hand, the development of malignancies during chronic immunosup‐
pressive therapy may be observed [2].
In  this  chapter,  we  discuss  an  important  and  interesting  area  of  research,  focused  on
identifying  the  relationships,  on  both  clinical  and  molecular  level,  between  ABD  and
malignancy.  Collectively,  the  literature  data  and our  own experience  indicate  that  ABD
may be associated with different malignant tumors, both cutaneous and affecting internal
organs.  However,  the  issue if  it  is  a  mere coincidence or  true pathogenetic  relationship
remains to be resolved. It is known that in a state of perpetual activation of immune system,
as in ABD, proinflammatory molecules (e.g. cytokines) may cause tissue damage leading
to chronic inflammation and subsequently increase the risk of carcinogenesis [3]. At both
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clinical  and molecular  level  ABD and malignancy-associated ABD (MAABD) may seem
similar; nevertheless, the pathogenesis of those entities plausibly is fundamentally distinct.
However,  broadly  observed associations  between ABD and cancer  indicate  that  various
molecular pathways may contribute to elevated risk of malignancy in these patients. Most
importantly,  the coexistence of  malignancy with ABD changes the management  of  such
patients compared to patients with ABD alone. For a long months and years, many cases
of ABD and MAABD are undiagnosed, misdiagnosed and subsequently mistreated due to
relative rarity and therefore low awareness of autoimmunity-driven blistering dermatoses
among practitioners. The time period elapsed between the first symptoms and diagnosis,
makes the time-onset relation between ABD and cancer usually uncertain.
Molecular  abnormalities  of  desmosomal  proteins  are  observed  in  ABD  and  epithelial
malignancies.  A  key  function  of  desmosomal  proteins  is  the  maintenance  of  adhesion.
However, in malignancy, where cells may separate, detach and metastasize, it is possible
that alterations in their expression may be the reason of carcinogenesis process. Interesting‐
ly,  the altered desmosomal protein expression and subsequent changes in cell-cell  cohe‐
sion  are  often  associated  with  signal  pathways  (e.g.  epidermal  growth  factor  –  EGF in
squamous cell carcinoma).
2. Autoimmune blistering dermatoses
ABD form a group of autoimmunity-driven diseases, where bullous lesions arise on the skin
and/or multiple mucosa. Diverse ABD are evoked by different triggering mechanism and are
characterized by different clinical onset, course and prognosis. Two main subdivisions can be
separated: ABD with autoimmunity to enzymes and ABD with autoimmunity to structural
proteins. The entities may be commonly distinguished by clinical, histopathological (presence
or absence of acantholysis and differences of its localization, level of blistering and the
composition of inflammatory infiltrate), immunohistochemical (localization and patterns of
deposits and autoantibody immunoglobulin class) and molecular examination (ELISA,
immunoblotting).
2.1. ABD with autoimmunity to enzymes
The  entity  is  represented  only  by  dermatitis  herpetiformis  (DH),  also  known  as  Duh‐
ring's disease -  chronic,  intensely itchy, blistering skin manifestation of the gluten sensi‐
tive enteropathy [4].  It  affects  symmetrically extensor surfaces of  limps and the trunk –
mainly buttocks and sacral  area,  where tiny vesicles,  papules or  even urticarial  plaques
occur in groups. The onset age is 20-60 years with peak about 35, and incidence ranging
from 10 to  39  per  100,000 persons,  depending on world region [1,5].  Patients  have IgA
autoantibodies to transglutaminases (TGs), that are considered major autoantigens in DH,
yet  other  antigens  were  also  reported  (antiendomysial,  antireticulin,  antithyroid  and
antinuclear antibodies) [5]. It is thought that granular/fibrillar IgA deposits in tips of dermal
papillae provoke neutrophile-mediated destruction of the dermal-epidermal junction (DEJ)
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and  forming  subepidermal  vesicle  [1,4,5]  Histopathologically,  microabscesses  in  dermal
papillae with neutrophile infiltration are seen in bioptate, obtained preferably of perilesion‐
al skin of the affected buttocks [5,6].
2.2. ABD with autoimmunity to structural proteins
This large group consists of several distinct circles of diseases with autoimmunity to different
antigens – desmosomal, hemidesmosomal and others.
2.2.1. Anti-desmosomal autoimmunity circle / pemphigus group
Anti-desmosomal autoimmunity circle or pemphigus group refers to a group of chronic ABD
characterized by the presence of autoantibodies (IgG or/and IgA) binding desmosomal
structures and keratinocyte cell-surface antigens, leading to acantholysis and intraepithelial
blister formation. The main antigens for pemphigus circle are desmoglein 1 (DSG1) and
desmoglein 3 (DSG3), yet there are forms of pemphigus without anti-desmoglein immuniza‐
tion [7]. The commonest subcircle is characterized by IgG-mediated autoimmunity and is
composed of:
• pemphigus foliaceus (PF) circle (PF, endemic PF, sebaceous PF, and PF herpetiformis,
paraneoplastic pemphigus, drug-mediated PF showing PF-indicative autoantibody profile),
• pemphigus vulgaris (PV) circle (mucosal-dominant PV, mucocutaneous PV, pemphigus
vegetans, and paraneoplastic pemphigus, PV herpetiformis, drug-mediated PV showing
PV-indicative autoantibody profile),
• pemphigus as a part of multiorgan autoimmunity syndrome,
• pemphigus shifting inside one circle or between circles,
• PV/PF-coexistence cases,
• paraneoplastic pemphigus (PNP) with neither anti-DSG3 nor anti-DSG1 antibodies [1].
A model disease for pemphigus circle and the commonest clinical type of pemphigus is
PV. This life-threatening chronic/acute ABD affects the mucocutaneous surfaces significant‐
ly debilitating quality of  life  [5].  The onset  age is  40-60 years,  and incidence ca.  0.7 per
100,000 persons [5,8].  Blistering in PV appears at  suprabasal  level  as an effect  of  tissue-
bound and serum IgG-driven autoimmunity against keratinocyte cell-surface antigens of
aforelisted cadherin superfamily [9], with desmoglein 3 (DSG3) as the main autoantigen.
The disease starts initially affecting oral mucosa (50-70%), that may remain the only site
involved, yet extraoral lesions may occur simultaneously. Intraepithelial blisters evolve into
aching  erosions  and  ulcers.  Predilection  sites  include  face,  parietal  region  of  the  scalp,
sternal and interscapular regions of the trunk, intertriginous sites (umbilicus, interdigital
spaces, scrotum, inguinal and axillary folds), scars and skin appendages – nail apparatus,
hair  follicles [1]  and areas with transitional  epithelium, what could be explained by the
change of desmoglein expression pattern.
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Histologically, suprabasilar blistering may be observed, whereas direct immunofluorescence
study (DIF) of perilesional skin/mucosa depicts IgG (mainly IgG4) pemphigus-type deposits
of fishing net pattern in intercellular spaces of the lower epidermis [1]. With virtually no
invasiveness, direct immunofluorescence study on a plucked scalp hair (hDIF) may serve as a
good alternative for DIF, visualizing pemphigus IgG, IgG1 and IgG4 deposits in outer root
sheath of hair follicle even in patients without cutaneous lesions [10]. Still used, indirect
immunofluorescence (IIF) test for presence of pemphigus IgG circulating autoantibodies is
regarded historical method and is widely replaced with molecular studies e.g. ELISA, enabling
assessment in serum, saliva or blister fluid [11].
PF, the less common pemphigus circle condition, usually affects the skin of the face, scalp and
trunk, but may generalize. The disease is characterized by autoantibodies binding DSG1, that
participate in blister formation at superficial level (granular layer). Although blister is a
primary PF lesion, it is hardly ever seen, as it rapidly evolves into crust-covered erosions [1,5].
Interestingly, as main PV DSG3-antigen (130kDa) and PF DSG1-antigen (160kDa) differ, that
corresponds with different blistering subtype and clinical features [5].
Concerning association with malignancy, PNP resembles clinically and histologically features
of PV and erythema multiforme [5]. However, it differs in autoantibody profile. PNP autoan‐
tibodies may target simultaneously multiple antigens – desmoplakin I and II, BP230, peripla‐
kin, envoplakin, plectin, 170kDa protein, desmoglein 1 and 3, desmocolin familly, and many
yet unknown proteins. PNP-type intercellular deposits can be visualized in IIF on transitional
epithelium of rat bladder. Circulating autoantibodies affects not only mucocutaneus epitheli‐
um, but may bind organ-specific antigens of gastrointestinal tract or bronchioli – e.g. causing
non-reversible and life-threatening constrictive bronchiolitis. Although rare, PNP is charac‐
terized with very high mortality [12].
2.2.2. Subepidermal autoimmune blistering dermatoses
Subepidermal ABD circle consists of chronic bullous diseases with autoantibodies binding
mostly structural proteins forming DEJ:
• Bullous pemphigoid (BP) circle (urticarial BP, BP herpetiformis, sebaceous BP, erythroder‐
mic BP, BP vegetans, pretibial BP, prurigo-nodularis-like BP, trauma-induced BP, pemphi‐
goid gestationis (PG), lichen planus pemphigoides (LPP), lamina lucida-type linear IgA
bullous dermatosis),
• Mucous membrane pemphigoid (MMP)/cicatrical pemphigoid,
• Pemphigoid Brunsting-Perry,
• Epidermolysis bulosa acquisita (EBA) circle (EBA, bullous systemic lupus erythematosus,
sublamina densa-type linear IgA bullous dermatosis),
• Linear IgA bullous dermatosis (LABD) (non-EBA circle LABD, non-BP circle LABD),
• anti-laminin gamma1 pemphigoid (former anti-p200 pemphigoid) [1].
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BP circle, the commonest ABD, is characterized by heterogeneous clinical patterns. However,
it has common molecular feature – autoimmunity to extracellular, non-collagenous NC16A
domain of BP180 antigen (BPAG2, collagen XVII alpha1) [1,5,13] and less often BP230
(BPAG2e, protein belonging to plakin family) [1,5]. It begins as a moderate pruritus, papular
lesions or urticarial plaques developing in months into chronic bullous eruption characterized
by well-tense blisters containing either serous or sanguineus fluid. The localized/generalized
lesions may be oval or round, and rupture easily over time [5]. The arciform or serpiginous
pattern they present is sometimes described as string of beans or cluster of jewels. Diverse
symptoms are consequence of targeting different epitopes of these components of hemides‐
mosome adhesion complex. It affects often elderly people in their 60's-90's [1,5] with incidence
of ca. 4.3 per 100,000 persons [8].
2.2.3. Other, vaguely characterized, autoimmune blistering diseases
There are also other autoimmune blistering diseases e.g. ABD with autoimmunization to
IQGAP1 protein, erythema multiforme with anti-desmoplakin 1 and anti-desmoplakin 2
antibodies, linear IgM gestationis dermatosis, linear IgM dermatosis with IgM gammapathy
and others that cannot be fitted into above categories, yet these are isolated cases with
unknown relation to malignancy.
2.3. Malignancies associated with ABD
The issue of association of malignancy and ABD causes much controversy among research‐
ers.  WHO reports  from 2008  indicated,  that  the  13% of  death  worldwide  is  caused  by
cancer,  being  the  major  cause  of  death  with  toll  of  7.6  million  people  per  year  [14].
Neoplasms are heterogeneous group of entities characterized by rapid creation of abnor‐
mal cells that grow beyond their usual boundaries, and which can then invade adjoining
parts of the body and spread to other organs [14].  The leading malignancies worldwide
are lung, breast, colon, stomach and prostate cancers [15]. Several malignant tumors were
reported  in  association  with  ADB,  including  lymphoproliferative  disorders  (Castleman's
tumor,  non-Hodgkin's  lymphoma,  chronic  lymphocytic  leukemia),  lung,  gastrointestinal,
prostate,  ovarian,  endometrial,  breast,  bladder,  renal,  laryngeal,  pancreatic  cancers,
thymoma and follicular dendritic cell sarcoma [16–22].
As ABD are relatively rare/regarded as rare conditions, there is limited data covering the
association with other diseases. Japanese retrospective study on malignancy in patients
suffering from pemphigus and pemphigoid observed incidence of 5.0% and 5.8% respectively
[17], whereas lesser studies set these numbers as 11.2% and 10.4% [16]. The association ratio
of malignancy with pemphigus increases by age, while no such correlation is found in
pemphigoid. No gender-predisposition in ABD was reported in these patients [16]. Interest‐
ingly, lung cancer was most common in pemphigus and gastrointestinal tumors (gastric cancer
in particular) in bullous pemphigoid [17]. Moreover, age-dependent malignancy-association
in PV patients under (6.5%) and above 60 years (15%) should not be omitted [16]. Studies on
BP and malignancy did not reveal age-correspondence [23].
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As far as anti-enzyme ABD is concerned, association of DH with subsequent development of
lymphoma seems well-documented [18,24,25]. It is possible that gluten intolerance is the factor
associated with malignancies. Some data suggested, that following a strict gluten-free diet is
protective against malignancy [26]. Moreover, researchers postulate that the risk of malignancy
decreases with time from diagnosis of gluten-sensitive enteropathy to nearly the same as
occurs in the general population. In light of above, it is postulated that the increased risk of
malignancy in patients with DH may be the result of a polyclonal stimulation of lymphocytes
by gluten that causes transformation into a malignant clone [18]. Still, in our over 20 years of
clinical/laboratory experience as a clinician/clinical researchers we do not recall a DH-
associated lymphoma patient.
There is a wide group of malignancies concomitant with ADB. Lung cancer has been reported
in coexistence with wide range of ABD: PV [17,27,28], PNP [29], pemphigus vegetans [30,31],
pemphigus herpetiformis [32], IgA pemphigus [33], BP [34] and MMP [35]. In some BP cases,
tumor resection led to complete recovery [36] supporting the thesis of close interrelation of the
diseases. Gastrointestinal tumors have been reported in association with BP [17,37], PNP [38],
pemphigus vegetans [39], PV [40–45] and MMP [46] sometimes with post-excisional remission
[47,48]. Both chronic leukemia and lymphoma have been reported with DH [49–51] and PNP
[52–54]. Based on few case reports, MMP [55–57] is not rare finding in leukemia. There has
been only one case of BP reported in patient with leukemia [58]. Thymoma and PV appears in
numerable patients [43] with post-excisional remissions not uncommon [59]. Among reported
thymoma-related ABD, there are also cases of PF [60,61], BP [62] and MMP [63]. Malignant
tumor of the pancreas seem to be generally connected to MMP [64,65] and sometimes PNP [66].
Renal neoplasm has been reported to occur in with BP [67–70] and occasionally with MMP [71],
PNP [72] and PF [73]. Ovarian cancer was incidentally described in relation with BP [74], anti-
laminin gamma1 pemphigoid [75] and MMP [76]. Concerning prostatic cancer, single cases of
PNP [77], pemphigus herpetiformis [78], PF [79] and MMP [80] were described in literature.
There are numerous case reports on ABD and breast cancer including predominantly BP
[20,81–85] and PV [86,87] with well-documented BP-lesion induction with radiotherapy.
3. Endogenous factors leading to breakage of self-tolerance in malignancy
Endogenous factors seem to be crucial for development of autoimmunity, as they form the
organism reaction to external threat.
3.1. Development of paraneoplastic immunity
The autoimmunity in cancer is developed by distortion of immune system, arising from central
tolerance disruption, peripheral immunity rearrangement and altering of self-antigens.
Cancer-associated impairment of the function of immune system may take place at many
stages. Rearrangement of T-cell receptor (TCR) genes proceeding in thymus cortex promotes
T-cell education to recognize major histocompatibility complex (MHC) molecules of self-cells.
It is a necessary condition for a T-cell to pass the positive selection process. The negative
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selection, being the following stage, is conducted in thymus medulla, where T-cells are exposed
to plethora of tissue specific self-antigens (TSAs) by medullary thymic epithelial cells. Self-
antigens presented to T-cells are previously processed, thus some T-cells expressing TCR with
high affinity to poorly presented antigens may evade negative selection achieving maturation
[88]. The process is controlled by autoimmune regulator (AIRE) transcription factor [89].
Autoaggressive thymocytes are being terminated in apoptosis. Impairment of any of these
stages – positive selection, negative selection, antigen processing, antigen presentation by
malignancy, might have impact on T-cell set and scope of activity in periphery. Thymoma is
the most common neoplasm of thymus, outrunning lymphomas, germ cell tumor, thymic
carcinoma, carcinoid tumors and others [90]. One of the syndromes in relation to thymoma is
paraneoplastic pemphigus, where diverse autoantibodies target diverse structural autoanti‐
gens. While pemphigus vulgaris (PV) and paraneoplastic (PNP) pemphigus may both target
the same antigen, the difference is within the range of them and difference in epitopes bound
(e.g. mucocutaneus PV preferably targets DSG3 N-terminal determinant, while PNP binds
multiple epitopes). Another distinctive feature is IgG subclass – predominant PV IgG autoan‐
tibody subclass is IgG4, while in PNP – subclass is IgG1 and IgG2 [1].
Some authors hypothesized that tumor cells alone may produce the autoantibodies [91,92].
The thesis of in-tumor immature T-cell improper maturation, without negative selection,
leading to autoaggression may be supported by findings in patient with follicular dendritic
cell sarcoma [93]. Malignancy is based on breakage of cell cycle guarding and dysregulation
of gene expression resulting in over- or underexpression of proteins. Via gene mutation, the
neoplastic cell changes the antigen suit, by exposing altered self-antigens or “hiding” those
already known. The reaction of immune system to cancer growth is immune cells recruitment
(T-cells, NK cells, mast cells) and inflammation by various mediators causing apoptosis of both
neoplastic and non-neoplastic cells. One T-cell can recognize many antigens presented by
different MHC molecules. The condition of recognition is the compatibility of antigen fragment
with lymphocyte TCR. Along with antigen sequestration theory, the determinants of cell
proteins released in tumor necrosis can be exposed by antigen presenting cells to matured T-
cells that migrate to lymph nodes. B-cells in response start to produce polyclonal antibodies
against novel tumor epitopes. However, T-cells may also react with cancer antigens starting
the chain of events leading to production of certain antibody cross-binding both neoplastic
antigens and self-antigens [90].
The role of immune system protection against malignancy can be exemplified by noticeable
higher cancer incidence in patients given immunosuppressive drugs impairing self/foreign-
antigens recognition. Hence hypothetically, the distortion in immune system function in ABD
may contribute to further susceptibility to the development of malignancy. Naive T-cell
activation in the periphery alone is thought to be insufficient for autoimmunity induction and
co-stimulation by CD28, a co-stimulatory molecule activating T-cells, seem to be necessary [94].
CD28 is able to bind CD80 molecule and CD86 molecule, constitutionally expressed on B-cells,
subsequently enhancing IgG antibody production [95]. CD80 molecule appear also scantly on
other antigen-presenting cells (APC – primarily B-cells, macrophages and dendritic cells) and
is upregulated after APC activation. Active APC present CD40, a ligand for CD40L expressed
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on active T helper cells. Ligation of CD40 on APC cells leads to increase co-stimulatory capacity
and antigen presentation ability enhancement. It is worth noticing that, CD80/CD86 is also
expressed on cells of diverse lymphomas (e.g. non-Hodgkin lymphoma and chronic lyphocytic
leukemia), that can act on behalf of APC, evading being recognized by the immune system. It
was suggested that T-cells may omit the “APC guarding stations” in lymph nodes and directly
infiltrate the tumor. Thus, the tumor itself may act as a "T-cell kidnapper" and support naive
T-cell infiltration, activation and differentiation into effector cells [96], hypothetically pro‐
gramming or "indoctrinating" T-cells to achieve autoimmune potential. Moreover, the study
based on collective incubation of non-malignant regulatory and cytotoxic T-cells with chronic
lymphocytic leukemia cells showed non-malignant T-cells cytoskeleton remodeling decrease
and vesicle trafficking decrease resulting in impaired synapse formation [97,98].
Fc receptors (FcRs) play essential role in the activation/inhibition of various cells in antibody-
mediated immune responses. Thus, FcRs function may be a key purpose in the treatment with
monoclonal antibodies (mAbs) therapy. Probably, FcRs may be a molecular link between ABD
and malignancies [99,100]. FcRs-targeting therapies are used for ABD and cancer, e.g. rituxi‐
mab, which is used in ABD and is the first anti-tumor mAb drug admitted by the US Food and
Drug Administration. It was demonstrated that Fc-receptor-dependent mechanisms contrib‐
ute substantially to the action of cytotoxic antibodies against tumors and indicated that an
optimal antibody against tumors would bind preferentially to activation Fc receptors and
minimally to the inhibitory partner FcγRIIB [101]. Interestingly, rituximab – the chimeric
monoclonal IgG1antibody specific for the B-cell marker CD20 – was recently approved for the
treatment of B-cell lymphoma. In vitro studies with rituximab have indicated that a direct pro-
apoptotic activity may be associated with this antibody [102].
3.2. Genetic predisposition
There seems to be a causative relation between HLA-association and autoimmunity in ABD,
especially in pemphigus [103–109] and pemphigoid [110], yet these observations may vary
geographically. HLA-DQB1*0301 allele, associated with MMP [111–114], was reported in
patients with esophageal squamous cell carcinoma [113], gastric cancer [115], HPV-associated
cervical neoplasia [116]. It was hypothesized, that the gene may have a role in T-cell recognition
of basement membrane antigens resulting in production of IgG autoantibodies binding
basement membrane antigens [117]. It is also possible, that the link exists between certain
malignancies and HLA or autoimmunity predisposition connected to defective apoptotic
genes. Nonetheless, there are few studies covering that field, so coexistence may also be purely
coincidental.
3.3. The role of cytokines
There is eventuality of oversecretion of certain cytokines regulating the mRNA expression and
polarization of certain T helper (Th) cell population [118,119], as the most common neoplasms
in relation to ABD seem to be lymphoproliferative malignancies. It has been reported that
qualitative as well as quantitative alterations in cytokine production can result in activation of
inefficacious effector mechanisms and therefore, complex and severe impairment in immune
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functions [119]. Polarization to Th1-mediated immunity via IL-1, IL-4, IL-5, IL-6, IL-8 and IFN-
gamma was observed in BP [120], while Th2-mediated reaction via IL-10 and IL-4, in conjunc‐
tion with decrease in IL-2 and IFN-gamma levels, were shown in PV [119]. The cytokines that
promote cancer growth (e.g IL-8 for colon and gastric cancer) [121,122] may collaterally initiate
Th population shift to the profile promoting ABD. Likewise, a proliferation inducing ligand
(APRIL) of TNF family plays an important role in several autoimmune diseases, including
ABD, and in several malignancies. Soluble APRIL level was reported to be raised in e.g. lung,
thyroid, lymphoid and gastrointestinal tumors [123,124], thus supposedly contribute to
dysregulation of immunity in cancer. B-cell activating factor (BAFF/BLyS), belonging to TNF
family, regulates B-lymphocyte proliferation and survival, also in B-cell lymphoproliferative
disorders [125]. Interestingly, serum of BP-, but not PV-patients, showed high titers of BAFF
[126]. It seems rational, that molecular mechanisms leading to increase of BAFF level in BP
patients may favor pathological lymphoproliferation.
3.4. Sex hormones
As some entities of ABD have sex-predisposition, just as some malignancies, the role of sex
hormones on development of MAABD need to be investigated. Certain tumors prevail in
female (breast cancer, non-Hodgkin lymphoma), in man (gastrointestinal tumor, laryngeal
cancer, Hodgkin lymphoma or kidney cancer) or are typical for one sex for anatomical reasons
(prostate cancer, ovarian cancer) [15]. Sex-associated distribution of PV and BP seems equal
with slight female dominance, while other ABD promote males (DH – 2:1) or are exquisitely
female domain (PG) [5,127]. Both T and B cells have estrogen, testosterone and prolactin
receptors. Furthermore, androgens and estrogens have an impact on the Th1/Th2 balance [128].
Therefore, menopause may be followed by change in cytokine profile affecting immune
response. Interestingly, studies on endocrine hormones in PV- and BP-patients have revealed
increased serum levels of both adrenocorticotropic hormone (ACTH) and hydrocortisone
[129]. It was hypothesized, that slight female predominance of women in PV may be contrib‐
uted to hormone replacement therapy (HRT) [130]. HRT is known risk factor for ovarian
cancer, yet the impact on neoplasm induction in breast cancer and endometrial cancer is
uncertain [131].
4. Exogenous factors: Epitope spreading and bystander effect
Multiple exogenous factors of diverse origin may contribute to trigger MAABD, e.g. drug-
induction of malignancy in ABD patients and, contrarily, self-antigen drug/virus/bacteria-
induced alteration. Drug-induced immunosuppression in ABD (e.g. with methotrexate) was
considered a prospective triggering factor for lymphoproliferative disorders [132]. Viral/
microbial factors could serve both as a trigger for autoimmunity and risk factor for malignancy.
It was hypothesized, that foreign antigens (e.g. viral, fungal, bacterial) may act as a superan‐
tigen in ABD induction or take part in epitope spreading phenomenon [133,134]. HBV, HCV,
H. pylori, T. gondii and CMV were reported to contribute to elicit ABD [135]. Viral infection
(TTV, HSV2, HHV6, HHV8, HSV1, HSV2, EBV, HBV, HIV-1, Coxsackie virus) [136–143] has
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been put forward as a causative agent of ABD-type autoimmunity in PV, PF, BP and pemphi‐
gus vegetans. There has been multiple factors suspected of prostatic cancerogenesis, including
viruses (BK, HSV2, HSV6, HSV11, HSV16, HSV18, HSV31, HSV33, HHV8, XMRV, CMV) and
microbial agents (Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum,
Neisseria gonorrhoeae and Treponema pallidum), yet data was inconclusive or supported no
relation [144–151]. Surprisingly, Epstein-Barr virus infection has been found statistically
associated with increased breast carcinoma risk [152]. It was speculated that the virus itself
may play a role in ABD induction [153,154]. The data covering the issue of exogenous factors
contributing to both malignancy and ABD is yet generally inconclusive.
Constant activation of immune system in ABD sustains chronic inflammation leading to tissue
degeneration by proinflammatory molecules. As a result, the risk of the neoplasy increases [3].
However, that relation could be two-sided. Inflammation in tumor nest stimulates and
modifies the immunity mechanisms. Furthermore, there is a hypothesis that the multiplicity
of target antigens in ABD may result from intra- and intermolecular epitope spreading. The
effect of epitope spreading in ABD is well-known fact and it seems to be a constitutional
compound of autoimmunity. Structural similarities between autoantigen epitope and to-be-
autoantigen epitope may lead to production of autoaggresive cross-reacting immunoglobulins
[9,155]. This phenomenon, which represents a broadening of the immune response from a
single epitope to additional epitopes, is also described in cancer and recent findings suggests
that epitope spreading may be a more significant predictor of effective immunity [156].
The initial anti-cancer immunity may ricochet to autoaggresion by epitope spreading and
bystander effect alike [157]. Local inflammation in the course of malignant tumor or chemo‐
therapy/radiotherapy treatment may result in enhanced autoantigen presentation that causes
T-cell priming, activation and expansion of additional specificity [158]. Therefore, in situations
where immunosuppressive/anti-cancer treatment is absent or ceased, anti-cancer response
may be responsible for development of autoimmunity to self-antigens characteristic for ABD.
5. Molecular mechanisms: The possible connection between malignancies
and ABD
ABD are characterized by autoantibodies against structural proteins of the skin, including
molecules of dermal-epidermal junction and desmosomes. Cancer progression is a complex
and multi-step process in which components of DEJ as well as a desmosomal molecules play
a pivotal role in the development of metastasis. Probably, more than 90% of human cancers
are of epithelial origin [159] and the autoimmunity against epidermal structures may play
important role in those carcinogenesis. Thus, probably DEJ/desmosomes is the first barrier in
tumor cells invasion. In light of this, understanding the molecular basis of pathological
autoinflammation induction in autoimmune blistering dermatoses in relation to the mecha‐
nisms of malignant transformation is paramount for early detection and treatment of epithe‐
lial-derived cancers [160]. However, the precise molecular mechanisms underlying the
association of malignancy with ABD still remain unknown. Nevertheless, understanding the
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link between the production of pathogenic autoantibodies in ABD and the development of the
associated neoplasy should facilitate the development of more specific diagnostic tests and
therapeutic strategies [160].
5.1. Malignancy in relation to the autoimmunity in pemphigus group: The role of
desmosomes components
Pemphigus group is characterized by presence of autoantibodies against desmosomal
cadherins. Research on human and animal models indicated that alternation in desmosomes
components may lead to tumor progression and metastasis. However, little is known about
the role of desmosome during cancer development [161]. It is clear, that the origin and
maintenance of epidermis requires the coordinated regulation of proliferation, adhesion,
migration and differentiation. Conceptually, desmosome complexes form when desmosomal
cadherins – DCs (desmogleins – DSGs and desmocollins – DSCs) participate in heterotypic
interactions that bring the plasma membranes of adjacent cells in close apposition [161]. The
cytoplasmic tails of these cadherins interact with plakoglobin and plakophilins.
The data describing desmosome protein expression during human cancer progression are
conflicting [161–163]. Molecular abnormalities of desmosomal proteins (DPs) are observed in
ABD and epithelial malignancies. However, in malignancy, where cells may separate, detach
and metastasize, it is possible that alterations in DPs expression may be the reason of carcino‐
genesis process. Several studies demonstrated that downregulation of DCs occurs during the
progression of cancers and is often correlated with and predictive of tumor metastasis
[161,162]. On the other hand, other studies reported overexpression of DCs during the cancer
progression, and this pattern is associated with poor prognosis [163]. The regulatory mecha‐
nism controlling DCs expression are scanty explained. As known, gene expression may be
modulated by genetic and/or epigenetic mechanisms and in this way may contribute to the
development of pathologic autoimmunity or malignancies. Genetic changes as mutation,
deletion, and gene rearrangement of DCs have been poorly found in cancer and ABD. Possible
mechanism may also involve post-translational modification of protein, like phosphorylation,
acetylation or methylation. In light of this, some data reported methylation of DCs, e.g.
methylation of DSC3 in breast cancer. It was showed, that DSC3 is downregulated in colorectal
cancer by DNA methylation [164]. Thus, further analysis of methylation status of DCs DNA
may be useful to predict clinical outcomes in patients with malignancy.
Alternatively, the possible link between desmosomal components and malignancy may be the
Perp protein. The Perp tetraspan membrane protein was originally identified as a transcrip‐
tional target of the p53 tumor suppressor upregulated during apoptosis [161,165]. However,
Perp may have function as a target of the p53-related transcription factor (p63) involved in
maintaining epithelial integrity by promoting desmosomal cell-cell adhesion. Electron
microscopy and biochemical analyses showed that the blistering phenotype observed in the
Perp-deficient epithelia is accounted for by both a reduction in desmosome number and
compromised desmosome complex formation. It is suggested, that pemphigus autoantibodies
may trigger internalization of Perp, which enhances adhesion defects [166]. Perp’s position
downstream of p63 and p53, as well as its essential role in normal desmosome function, suggest
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that it may be a target for mutation in human blistering diseases or cancer [167]. An interesting
issue remains why a p53 target would play such a prominent role in adhesion in the skin. It
was suggested [167], that this role relates to Perp being a key component of the transcriptional
program for stratified epithelial development and maintenance specified by the p53 family
member p63. Perp is a transcriptional target of p63 during development and in mature mouse
skin [168]. Beyond a role in epithelial function, Perp’s status as a p53 target involved in
apoptosis may suggest a potential role as a tumor suppressor. Given that loss of both p53 and
p63 cooperate in tumorigenesis, loss of Perp similarly may be expected to promote cancer
development in some context. The future analysis of Perp will provide new insight into the
role of desmosomes in epithelial homeostasis and cancer [167]. It was disputed, that Perp-
deficiency promotes cancer by enhancing cell survival, desmosome loss and inflammation,
and fundamental role for Perp and desmosomes in tumor suppression [161]. Interestingly, it
seems that DSC3 is a p53 response gene and addition of wild-type p53 was found to be
sufficient to induce expression of DSC3 in breast cancer [169]. Thus, it was of great interest to
investigate whether this pathway is also active in tumor cells. In light of above, the induction
of p53 may have impact on expression of DCs [164].
Malignancy may be also associated with pemphigus group via pemphigus-antibodies-induced
signaling pathways. Thus, cadherins expression can function as a tumor and invasion
suppressor due to its participation in processes such as morphological differentiation and
contact inhibition of growth and motility. Several different molecular mechanisms for
perturbation of cadherin function in epithelial tumors are reported: (i) transcriptional or
genomic regulation of cadherin expression, (ii) mutations (e.g. deletion, insertion) of cadherin
or catenin genes and (iii) regulation of adhesive function by signaling pathways. A signaling
cascade initiated by pemphigus vulgaris antibodies may results in reduced availability of
plakoglobin and abrogation of its function as transcriptional repressor of the proto-oncogene
c-Myc. This in turn results in accumulation of c-Myc. Moreover, c-Myc expression is commonly
upregulated in tumors. There is also evidence, that etiology of some skin cancer (e.g. BCC)
may be dependent on several signaling pathways [170], which can be shared with pathological
autoimmunity induction in pemphigus group. Other signaling pathways may engagement of
Src, Wnt, hedgehog, epidermal growth factor receptor (EGFR) kinase (EGFRK), cAMP, protein
kinases A and C (PKC), phospholipase C, mTOR, p38 MAPK, JNK [166]. Especially, it is
postulated that DSG3 is a key player in Src signaling and overexpression of DSG3 elicited a
phenotype similar to this with increased Src activity. Interestingly, this phenotype may be
observed in some kind of cancers (e.g. SCC) [171]. Moreover, it is estimated that 35% of cancers
show increased MAPK activity [172]. On the other hand, MAPK is involved in the process of
acantholysis in pemphigus group.
Furthermore, some data [173,174] demonstrated possibility that switching of DCs could play
an important role in the development of some kind of cancer. Tumor development is in part
characterized by the ability of cells to destruct of cell-cell adhesion and invade the surrounding
tissue. Perhaps, the disturbances in desmosomal cadherin (as DSCs) expression could affect
beta-catenin signaling [174]. It is known, that increased beta-catenin signaling is a common
causative event in some kind of cancer (e.g. colorectal cancer), thus desmocollin switching
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could play a contributory role in the initiation of early stages of cancer. In light of this, the
evidence that altered expression of desmosomal proteins in various human malignancies has
been accumulating.
5.2. Malignancy in relation to the autoimmunity in subepidermal blistering dermatoses:
The role of the DEJ proteins
Pathogenesis of blister formation in subepidermal blistering dermatoses is associated with
destruction of dermal-epidermal junction and anchoring fibers. Recent studies shown inter‐
esting function of the hemidesmosome (HD) components in signal transduction, involving
effect on cell behavior in tumor invasion [175]. Data indicated altered expression of DEJ
proteins at different stages of carcinogenesis, what may suggest the association between tumor
progression. Aberrant expression of DEJ proteins, which are associated with subepidermal
blistering dermatoses (e.g. BP180, BP230, alfa6beta4 integrin, laminin-322) in epithelial cancers
was demonstrated, what may indicate their role in tumor development and invasion [175].
Reduced expression of HD components may results in the detachment of cells from the
basement membrane, facilitating piling or migration of cells [176]. On the other hand, carci‐
noma cells may upregulate the expression of HD molecules to enhance the attachment capacity
of metastatic cells to the DEJ at the metastatic site in order to establish metastatic growth.
The aberrant expression of DEJ component may reflect dysfunction of HD, that occurs as an
early event in multistep carcinogenesis of epithelium [177]. Downregulation of BP180 – one of
the major autoantigen in bullous pemphigoid – was found in basal cells in mild dysplasias,
upregulation of BP180 in suprabasal keratinocytes in moderate and severe dysplasis as well
as in the central cells of squamous cell carcinomas (SCC; G2 and G3) using immunohisto‐
chemical (IHC) and in situ hybridization (ISH) methods [175]. Furthermore, this group of
researchers indicated that overexpression of BP180 was found at the invasive front of the
tumors. Authors suggested that reduced BP180 expression at the early step of carcinogenesis
may reflect disturbed keratinocyte adhesion to the basement membrane. BP180 gene expres‐
sion is significantly induced by a tumor promoter PMA [175]. Previous findings obtained by
the same authors revealed reduced BP180 expression in the peripheral cells of carcinoma
islands in solid and keratotic basal cell carcinomas (BCC) and in the basal cells of invading
buds in superficial BCCs [178]. The altered expression of DEJ proteins is likely to coincide with
the disassembly of HD, which is an essential step in keratinocyte migration and carcinoma cell
invasion [175]. Moreover, downreguation of BP180 and other hemidesmosome components
was previously detected in vivo in prostate cancer and in the invasive cells of ductual mam‐
mary carcinoma [179,180]. On the other hand, upregulation of HD components has been
reported in a variety of SCCs [177,181]. It was argued that BP180 upregulation in carcinoma
cells at the invasive front of malignant tumors is important in the carcinoma cell migration
[175]. Other study described upregulation and altered distribution of BP230 and alfa6beta4
integrin in the areas of invasive growth of head and neck SCCs [181]. PMA is a potent tumor
promoter capable of inducing several genes that have a role in carcinogenesis and tumor
invasion [182]. It is known, that laminin-332 gamma2 chain gene promoter is one of the targets
of PMA activation, occurring via interaction with the activator protein 1 complexes [183]. The
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relationship of BP180 to malignancy is discussed. BP180 has possible phosphorylation sites
and may by phosphorylated in SCC [177]. Enhanced expression and abnormal distribution of
BP180 in various precancerous and cancerous tissues was revealed, including e.g. SCCs and
Bowen’s disease [177].
As it was demonstrated that expression of BP180 was decreased or absent in cutaneous
neoplasms [184], some authors speculated that some type of carcinomas itself might expose
BP180 antigenic epitope, which would normally be hidden, thus inducing the production of
autoantibodies that lead to the onset of BP [185]. It was proposed that BP180 neoexpression
could be associated with early/malignant transformation of keratinocytes as widely expression
of BP180 was demonstrated in SCC in contrast to normal skin, where this protein is restricted
to basal keratinocytes [186].
Laminin-322 (previously named laminin-5) is the main autoantigen in anti-epiligrin cicatricial
pemphigoid, mucouse membrane pemphigoid. Laminin-332 and alfa6beta4integrin may play
an important role in tumor progression via activation of phosphatidylinositol-3 kinase
signaling (PI3K) [187]. There was shown, that it is highly expressed in several types of
squamous and other epithelial tumours [188]. Moreover, in these tumors, laminin-322 shows
tendency to accumulate at the interface of the tumor with the surrounding stroma, and
expression of this proteins correlates with tumor invasiveness [188]. Interestingly, keratino‐
cytes from patients with junctional epidermolysis bullosa, that did not express laminin-322 or
beta4integrin, showed a lack of tumorigenecity in immunodeficient mice after transformation
[188]. Perhaps, the binding of collagen VII to laminin-322 may be essential for tumorigenesis
[188]. Furthermore, the laminin-322-derived signaling is an important component of tumori‐
genesis. As mentioned above, constitutive activation of the PI3K pathway leading to RAC1
GTPase activation may be the triggering factor inducing tumor invasion.
6. Case reports of MAABD
As the association between ABD and malignancy is noted in many case reports, the question
of causal connection is raised. There are three situations possible concerning the relation: i)
malignancy preceding ABD, ii) malignancy coexisting with ABD, iii) malignancy following
ABD. For a long months and years, many cases of ABD are undiagnosed, misdiagnosed and
subsequently mistreated due to relative rarity and therefore low awareness of ABD and its
symptoms. The time period elapsed between the first symptoms and diagnosis, makes the
time-onset relation between ABD and cancer usually uncertain.
Here, based on our personal clinical/laboratory/research experience, we present a dozen of
memorable/representative patients with association of malignancy, both cutaneous and
internal, and ABD over the last decade. Unfortunately, usually there is no experimental data
indicating if it is a random coincidence or cause-and-effect relationship in individual patient.
Still, the diagnosis of such a concurrence increases mortality.
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6.1. Anti-desmosomal autoimmunity circle / pemphigus group cases
6.1.1. Case 1 — Mucocutaneous pemphigus vulgaris / lung cancer
An  elderly  female  with  painful  oral  erosions,  flat  white-speckled  infiltrations,  mucosal
edema  and  enlarged  submandibular  lymph  nodes  was  admitted  to  oncology  center
outpatients.  Histopathological  examination of  the retromolar  mucosa of  the left  alveolar
process of maxilla showed paraepidermoid epithelium with focal high-grade dysplasia and
few neoplastic cells.
Due  to  improper  biopsy  technique  full  examination  of  the  material  was  impossible.
Therefore,  the patient was readmitted to the oncology ward, with tentative diagnosis of
carcinoma  planoepitheliale  with  bilateral  metastases  to  neck  lymph  nodes,  for  bilateral
selective lymphadenectomy and probational excision of the lesions at right buccal region
and  left  soft  palate.  Histopathological  examination  on  probational  biopsy  showed  mu‐
cous membrane fragments with features of basement membrane disruption and acantholy‐
sis.  There  was  abundant  infiltration  consisting  of  lymphoid  cells  with  plasmocyte
prevalence and presence of granulocytes. The overall image did not support the diagno‐
sis  of  carcinoma  planoepitheliale,  yet  suggested  pemphigus.  Chest  x-ray  showed  left-
sided pleural effusion with costodiaphragmatic recess filling. At the posterolateral side of
the lung, thin layer of liquid reaching 7th rib in the posterior axillary line was observed.
Ultrasonography of the neck showed non-enlarged thyroid gland (10 ml of volume) with
hypoechogenic node (11 mm x 8 mm) and 3 lesser hypoechogenic nodes of diameters up
to 4 mm in the left lobe. Enlarged lymph nodes, with narrow lymph sinuses (up to 15 mm
x 8 mm) and unclear character, were seen bilaterally in the upper part of the neck vessels
beyond mandibular angles.
The patient was directed to dermatological ward for further diagnostics. Laboratory tests
showed increased sedimentation rate. DIF of perilesional skin of the vulva revealed IgG(+),
IgG1(++) and C3(+) deposits in the intercellular spaces of the spinous layer of epidermis. hDIF
on pulled-out hair revealed IgG(+), IgG1(+) and IgG4(+) deposits in the intercellular spaces of
the outer root sheath. DIF of larynx mucosa showed fragmented specimen, mainly without
epithelium. There was fragmented epithelium consisting of several cells at the specimens
margin (evident acantholysis) with surrounding noticeable IgG(+/-) and C3(+/-) deposits. IIF
study on monkey esophagus revealed circulating IgG class of pemphigus-type autoantibodies
against desmosomal proteins of keratinocytes – titer above 1/80. On the basis of abovemen‐
tioned tests the diagnosis of mucocutaneous PV was reached.
After amelioration of the lesions, due to pulse steroid treatment, she was dismissed from the
ward. Two months later, she suffered from aggravation of mucosal erosions, haematopnoe
and dyspnoe. The woman was admitted to oncology center, where chest computed tomogra‐
phy (CT) scan visualized solid mass in the left lung (Fig. 1A). Via bronchofiberoscopy,
carcinoma planoepitheliale of the left lung (G4) with hepatic metastases was diagnosed.
Palliative radiotherapy (20 Gy/T) of the mediastinal/left pulmonary region led to aggravation
of mucocutaneous PV (Fig. 1B).
Malignancy in Relation to Autoimmune Blistering Dermatoses: Molecular and Clinical Aspects
http://dx.doi.org/10.5772/55240
173
6.1.2. Case 2 — Mucocutaneous pemphigus vulgaris / oropharyngeal cancer
A middle-aged man observed blisters localized in the interscapular region and the posterior
aspect of the neck (Fig. 2B, C). Simultaneously, he suffered from excruciating sore throat and
dysphagia. He was consulted by ENT-specialist and subsequently was directed to oncology
center for further diagnosis and treatment. Histological material obtained during laryngolog‐
ical diagnostics revealed carcinoma planoepitheliale keratodes invasivum of the right palatine
tonsil, soft palate and uvula (T3N2M0) with metastatic focus in lymph node (Fig. 2A).
Therefore, the patient underwent excision of the lesion with bilateral modified cervical
lymphadenectomy. Neck ultrasound imaging visualized hypoechogenic polycyclic tumorous
mass (43 mm x 25 mm) associated with lower pole of parotid gland with numerous small
satellite nodules of diameter up to 6 mm and dissolved reactive lymph nodes up to 7 mm of
length. The patient was treated with Intensity Modulated Radiation Therapy (IMRT) – 6 MeV
photons for 34 cycles (68 Gy/t). Due to lesions regarded as notable cutaneous radiation
syndrome of the neck (II* according to EORTC/RTOG scale), the few last cycles were dimin‐
ished by 1 fraction and postradiative topicals were applied. Interestingly, the bullous lesions
exacerbated (Fig. 2D) and appeared on the thorax, abdomen and limbs (Fig. 2E). No mucosal
involvement was present at that time.
Due to above symptoms, he was consulted by the dermatologist. Histology of the skin revealed
suprabasilar separation and acantholysis in the upper epidermis (Fig. 2F). IIF on monkey
esophagus revealed circulating IgG class pemphigus-type antibodies against desmosomal
proteins of keratinocytes – titer 1/320. DIF on the perilesional skin of the back showed IgG(+),
IgG1(+), IgG4(+++) and C3(+) deposits in intracellular spaces of lower layers of epidermis (Fig.
2G). DIF of the plucked hair showed IgG4(+++), IgG1(++), IgG(++) and C3(+/-) deposits in
intracellular spaces of outer hair sheath (Fig. 2H). Performed tests supported the diagnosis of
mucocutaneous PV.
Four months later, patient was admitted to dermatological ward with numerous blisters and
erosions on the skin of the thorax, back, limbs and head. Reddish postradiative aggravated PV
lesions, which healed later with aggressive immunosuppressive treatment, with marginal
blistering notably limited to the anterior surface of the neck, showed no visible reepitheliali‐
zation. Numerous painful erosions presented on oral mucosa disabling patient's feeding and
resulting in 10 kg weight loss. ELISA study revealed the presence of anti-desmoglein 1 (DSG1)
IgG of titer 130.34AU/ml (cut-off point 41AU/ml) and anti-desmoglein 3 (DSG3) IgG of titer
>150AU/ml (cut-off point 40AU/ml). IIF performed on rat bladder did not reveal serum
antibodies of paraneoplastic pemphigus (PNP) type. Consulting laryngologist described
numerous erosions of buccal and oral mucosa, yet noticed no features of recurrence of
malignancy. The case was reported in literature [189].
6.1.3. Case 3 — Pemphigus foliaceus / pseudomyxoma peritonei
An elderly female was admitted to dermatological ward with numerous erythematous
plaques, blisters and non-healing erosions covered with crusts – on the scalp, trunk and limbs
(Fig. 3A, B). Her medical history was significant for angina pectoris, angioplasty (PTCA) with
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stent implantation due to myocardial infarction, hypertension, hypercholesterolemia, diabetes
mellitus type 2, hiatal hernia and epigastric hernia.
Figure 1. A. Chest CT of an elderly PV patient showing tumor in the left lung. B. Aggravation of mucocutaneous PV
after palliative radiotherapy (radiotherapy-induced PV lesions).




Figure 2. A. Carcinoma planoepitheliale keratodes invasivum in lymphoid tissue. H+E staining. Courtesy of Prof. J. Brę‐
borowicz. B. Numerous erosions on non-inflammatory skin of the back, some of them covered with brownish-greenish
crusts. C. Erosions on non-inflammatory skin of the face and neck. Scar after the surgical excision of the cancer. D. Nu‐
merous merging erosions, some covered with bloody and greenish crusts on the skin of the neck area subjected to
radiotherapy. E. Erosions covered with crusts around the nipple (a natural body orifice area). F. Suprabasilar separation
and acantholytic blister in the upper epidermis. H+E staining. G. DIF of perilesional skin of the back: pemphigus IgG4
deposits in lower epidermis. H. DIF of plucked scalp hair: pemphigus IgG4 deposits in outer root sheath.
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Initially, lesional skin sample examined by the cutaneous pathologist showed thin epidermis
with fissures and flat vesicles in upper layer with slight acantholysis. Perivascular inflamma‐
tory infiltrates with prevalence of lymphocytes and eosinophils, focally involving the epider‐
mis, were seen in the dermis. DIF test revealed deposits of IgG(+), IgG4(++) and C3(++) in
intercellular spaces of epidermis. Marked acantholysis was visible and upper layers of
epidermis were absent. Serum IgG, but not IgG4, autoantibodies of pemphigus type against
desmosomal proteins of keratinocytes were present in IIF on rabbit labial mucosa and normal
human skin, of titers respectively 1/40 and 1/160. The diagnosis of PF was made. She was
treated with oral steroids and cyclophosphamide achieving remission before dismissal.
Six years later she was readmitted to dermatological ward due to aggravation of PF. IIF study
on monkey esophagus showed serum IgG4 autoantibodies of pemphigus type against desmo‐
somal proteins of keratinocytes – titer 1/80 (Fig. 3C). Abdominal ultrasonography revealed oval
hyperechogenic solid mass (12 mm x 14 mm) in the middle part of the right kidney medulla
suggesting  kidney  tumor.  Two-phased  abdominal  CT  scan  visualized  hypodensic  well-
delineated lesion (transverse diameter ca. 10 mm) in right renal medulla (suggestive of angio‐
myolipoma) characterized by density of adipose tissue, without contrast intensification.
The patient was supervised for years by dermatology practitioner. Due to increase of waist
circumference, she was suggested to visit gynecologist. In gynecological control, the physician
found right adnexal mass. The patient was directed urgently to gynecologic ward with
tentative diagnosis of ovarian cancer, where she underwent hysterectomy with adnexotomy,
omentectomy and appendectomy. The tumor was described by the histopathologist as low
grade appendiceal mucinous neoplasm (pseudomyxoma peritonei) with metastasis to right
ovary and omentum. Since then, she regularly visited gynecological oncologist.
Figure 3. A. Erythematous plaques and crusts on the scalp of the head. B. Erosions and blisters on the back. C. IIF on
monkey esophagus: pemphigus IgG4 autoantibodies. PF recurrence in the course of ACE-inhibitor treatment for myo‐
cardial infarction.
6.1.4. Case 4 — Pemphigus foliaceus / squamous cell carcinoma of the thorax
A middle-aged man was consulted by dermatological specialist due to disseminated eryth‐
ematous plaques. The lesions were preceded by three months of uncomfortable itching on
hands and feet. He was not diagnosed beforehand and was solely treated with topical steroids.
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Therefore, he was directed do dermatological ward with tentative diagnosis of
pemphigus/PNP for further diagnostics and treatment.
On admission, he presented erythroderma (Fig. 4A) and notable exophytic tumor on anterior
surface of the thorax (c.a. 13 cm of diameter),  clinically carcinoma verrucosum (Fig. 4B).
Laboratory tests showed anemia, increased sedimentation rate and CRP. Histology of the
perilesional skin showed marked acantholysis (Fig.  4C).  Tumor margin bioptate showed
clustered isles of atypic cells with fine keratin pearls giving overall image of highly differentiat‐
ed squamous cell carcinoma (SCC) G1 (Fig. 4D). IIF on monkey esophagus proved the pres‐
ence of serum IgG pemphigus-type antibodies against desmosomal proteins of keratinocytes –
titer 1/160, yet IIF on rat bladder for serum PNP-type IgG was negative. ELISA test showed serum
anti-DSG1 IgG level >200 RU/ml (cut-off point 20 RU/ml), yet did not revealed serum anti-
DSG3 IgG – level 0 RU/ml (cut-off point 20 RU/ml). DIF of the perilesional skin visualized IgG(+),
IgG1(++) and IgG4(++) deposits in the intercellular spaces of higher layers of epidermis and C3(+
+) deposits in the intercellular spaces of lower layers of epidermis (Fig. 4E). hDIF showed IgG(+),
IgG1(+) and C3(+) deposits in the intercellular spaces of outer root sheath (Fig. 4F). With clinical
and histological findings and molecular findings, the diagnosis of PF was made. After achiev‐
ing  dermatological  improvement  with  doxycycline,  antihistamine  drugs  and oral/topical
steroids, patient was directed to oncology ward for SCC therapy.
Figure 4. A. Disseminated erythematous plaques and crusts on the back. B. Exophytic tumor on anterior surface of the
chest. C. Histology of the perilesional skin: Acantholysis. H+E staining. D. Histology of the tumor margin: Clustered isles
of atypical cells with fine keratin pearls. Highly differentiated SCC. H+E staining. E. DIF of perilesional skin: IgG4(++)
deposits in the intercellular spaces of higher layers of epidermis. F. hDIF of plucked scalp hair: IgG(+) deposits in the
intercellular spaces of outer root sheath.
6.1.5. Case 5 — Mucocutaneous pemphigus vulgaris shifting from mucosal dominant form / lower lip
squamous cell carcinoma
An elderly man treated for lower lip squamous cell carcinoma (SCC planoepitheliale kerato‐
des; G2) that developed in lesions showing histological features of PV (Fig. 5E, F) suffered from
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painful erosions on oral mucosa dating back several months (Fig. 5A). Subsequently, the
blistering lesions and oozing erosions appeared on the skin (Fig. 5B, C). He called the derma‐
tology professional and was directed to dermatological ward for diagnosis and treatment.
His laboratory tests showed increased sedimentation rate. Chest x-ray revealed fine atelectasis
in the inferior aspect of the right lung. Ultrasonography of the abdomen showed non-echogenic
area (16 mm x 18 mm) with intramural calcification and features of a cyst within VII segment
and hypoechogenic lesion (dia. of 12 mm), probably angioma, in VI/VII segment of the of the
right lobe of the liver. Two lesser cysts (up to dia. 5 mm) were found in left lobe. Gallstone
(dia. 18 mm) was depicted in gall bladder, while right kidney showed sonographic features of
hydronephrosis. An intravenous urogram (IVU) proved the presence of renal stone in right
ureteropelvic junction, causing obstruction and dilatation of the pelvicalyceal system. In
Tzanck test rounded acantholytic cells were present (Fig. 5D). Skin bioptate was characterized
by the pathologist as PV material. hDIF showed IgG(++) and IgG4(+) deposits in intercellular
spaces of outer root sheath (Fig. 5G). DIF on skin lesion margin showed IgG(+), IgG4(++) and
C3(+) deposits in intercellular spaces of the lower spinous layer of epidermis (Fig. 5H). IIF on
monkey esophagus revealed circulating IgG pemphigus-type antibodies against desmosomal
proteins of keratinocytes – titer 1/320. ELISA test with patient's serum revealed serum anti-
DSG1 and anti-DSG3 IgG class autoantibodies – levels respectively 133.81 RU/ml (cut-off point
41 RU/ml) and > 150 RU/ml (cut-off point 40 RU/ml). The diagnosis of mucocutaneous PV
(shifting from mucosal dominant PV) was established. He was treated with pulses of high dose
intravenous steroids combined with oral/topical steroids and doxycycline as a fundamental
therapy with satisfactory effect.
6.1.6. Case 6 — Mucosal dominant pemphigus vulgaris / breast cancer
An elderly female, five years after right-side mastectomy due to breast cancer (invasive ductal
carcinoma; G1; pT1cpN1Mx), was admitted to dermatological ward with painful non-healing
erosions of oral and tongue mucosa. Her medical history was significant for diabetes mellitus
type 2, arterial hypertension, diverticulosis, hemorrhagic gastritis and past episodes of deep
vein thrombosis in the legs and thrombosis of the right central retinal vein. hDIF revealed IgG
(+++), IgG1(++), IgG4(+++) and C3 deposits in intercellular spaces of outer root sheath (Fig.
6A). DIF on the perilesional mucosa showed IgG(+), IgG1(++), IgG4(+)and C3 deposits in
intercellular spaces of lower layers of oral epithelium (Fig. 6B). IIF on monkey esophagus
showed circulating IgG pemphigus-type antibodies binding spinous layer desmosomal
proteins of keratinocytes – titer 1/160. Serum PNP-type autoantibodies were absent in IIF study
on rat bladder transitional epithelium. ELISA study revealed elevated anti-DSG3 IgG level:
112.83 AU/ml (cut-off point 40 AU/ml), while IgG anti-DSG1 level was normal: 34.49 AU/ml
(cut-off point 41AU/ml). Both laboratory tests and immunopathological findings supported
the diagnosis of mucosal dominant PV. She was treated with oral methyloprednisolone,
doxycycline and cyclophosphamide.
Because of her medical history, she was gradually deprived of methyloprednisolone, that
resulted in an aggravation of PV within a month and need for urgent hospitalization. She was
admitted with diffused erosions and blisters both on the skin and oral mucosa. Laboratory




Figure 5. A. Mucosal erosions in patient with lower lip SCC and mucocutaneous PV. B. Fragile blister on the hand. C.
Pemphigus vulgaris imitating paronychia. D. Positive Tzanck test: rounded acantholytic cells suggestive for PV. E. Su‐
prabasilar cleft with acantholysis in the lower lip specimen showing also features of SCC. H+E staining. F. Lower lip
SCC. H+E staining. Courtesy of Prof. J. Bręborowicz. G. hDIF: pemphigus IgG deposits in intercellular spaces of outer
root sheath. H.DIF showing IgG pemphigus-type deposits.
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tests revealed elevated CEA level – 8.05 ng/ml (cut-off point 5 ng/ml) with normal levels of
other cancer biomarkers (CA19-9, Ca125, AFP). She was treated with cyclophosphamide,
doxycycline and high doses of both intravenous and oral steroids.
She was readmitted to the ward six months later with erosions on buccal mucosa, base of the
mouth, soft palate and epiglottis. Laboratory tests revealed elevated CA19-9 level: 843.8 U/ml
(cut-off point 37 U/ml). After achieving remission of lesions, she was directed to oncology
outpatients to screen for malignancy.
Figure 6. A. hDIF visualizing IgG1(++) deposits in the outer root sheath. B. DIF of perilesional mucosa revealing IgG1(+
+) deposits in intercellular spaces of lower layers of oral epithelium.
6.1.7. Case 7 — Pemphigus foliaceus / squamous cell carcinoma of external nose and upper lip
A middle-aged man with exophytic ulcerative nasal tumor was diagnosed with paranasal
sinuses roentgenogram revealing massive shade of polycyclic outline. Surgical excision of the
external nose tumor infiltrating upper lip was performed in oncology center (Fig. 7A).
Exophytic lesion was described by a pathologist as carcinoma planoepitheliale keratodes (G2).
The patient was frequently monitored in oncology outpatients finding no features of tumor
recurrence.
Two years afterward, erythemous plaques with flaccid serous blisters, oozing erosions and
crusts  appeared  on  lower  limbs.  It  took  several  weeks  until  lesions  generalized  and
occupied trunk, limbs, head and intertriginous regions forming vast desquamative surfaces
of flaky puff pastry-like appearance (Fig. 7B). Mucous membranes remained free of lesions.
Due to ineffective ambulatory management, he was directed to dermatological ward with
tentative diagnosis of PF.
Histological features of perilesional skin supported PF diagnosis. IIF on monkey esopha‐
gus  revealed  serum  IgG  pemphigus-type  antibodies  against  desmosomal  proteins  of
spinous layer of epidermis – titer 1/320, yet IIF on rat bladder epithelium as a substrate
did not detected circulating PNP-type autoantibodies. DIF of perilesional skin visualized
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well-defined  IgG(+++)  and  IgG4(+++)  deposits  in  intercellular  spaces  of  lower  layers  of
epidermis and linear C3(+) deposits alongside DEJ (Fig. 7C). Serum anti-DSG1 IgG ELISA
was positive – level >150 AU/ml (cut-off point 41 AU/ml), whereas serum anti-DSG3 IgG
ELISA proved negative – level 6.20 AU/ml (cut-off point 40 AU/ml). The molecular tests
confirmed the PF diagnosis. He was treated with oral/intravenous steroids and cyclophos‐
phamide, azathioprine and doxycycline as adjuvant treatment. The compliance in ambula‐
tory care was poor as the patient repeatedly was treated in dermatological ward with IIF
IgG pemphigus-type antibody titer reaching 1/2560.
Figure 7. A. Nose stump after tumor excision. Courtesy of S. Stusek MD. B. Flaky puff pastry-like desquamative lesions
on the trunk. Courtesy of S. Stusek MD. C. DIF of perilesional skin: intense pemphigus IgG4(+++) deposits.
6.2. Subepidermal autoimmune blistering diseases
6.2.1. Case 8 — Bullous pemphigoid / colon cancer
An elderly man was directed to chirurgical ward due to ileus. He underwent left hemicolec‐
tomy and forming of colostomy because of appendicitis, chronic peritonitis and colon cancer.
Histopathological examination of the excised material revealed partially gelatinous tubular
adenocarcinoma (G2; T4N0M0) infiltrating pericolic adipose tissue (Fig. 8B).
After the surgery, eczematous vesicular oozing eruption appeared on the surrounding of the
stomy (Fig. 8A), while itchy well-tense bullae occurred on the skin of the back covering trunk
and limbs in a few weeks. Histopathological and immunopathological tests were performed
in dermatological outpatient ward two years after operation. Histology of the perilesional skin
showed subepidermal vesicle filled with inflammatory cells with predominance of eosinoi‐
phils (Fig. 8C). Perilesional skin DIF revealed linear deposits of IgG4(++) and C3(+++) along
dermal-epidermal junction (DEJ) (Fig. 8D). IIF, performed on monkey esophagus as a sub‐
strate, was negative for IgG serum autoantibodies against desmosomal proteins of keratino‐
cytes and basement membrane antigens. ELISA anti-BP180NC16a examination was positive
for serum IgG antibodies against BP180 – titer 60.47 U/ml (cut-off point 9 U/ml), that enabled
the diagnosis of trauma-induced and paraneoplastic BP at the molecular level. Control chest
X-ray and ultrasonography of the abdomen did not showed neoplasm.
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BP tend to manifest in natural and iatrogenic orifices featured by transient epithelium (e.g. the
scar or the stomy site). It may be possible, that malignant tumor causing pathological immu‐
nization triggered the onset of this subepidermal dermatosis. The case is a hallmark of
literature data [191–193].
6.2.2. Case 9 — Bullous pemphigoid / family history of renal cancer
A middle-aged female was directed to dermatological ward for diagnostics and treatment of
disseminated itchy blisters and vesicles on erythematous skin (Fig. 9A, B) dating back two
months. Her family history was significant for renal cancer coexisting with a subepidermal
IgG-mediated bullous dermatosis, most likely BP, in grandmother. Her laboratory test were
noncontributory. Immunohistochemical study showed subepidermal blister with neutrophil
elastase (NE) deposits (Fig. 9C). IIF on monkey esophagus was positive for serum IgG
pemphigoid-type antibody against DEJ proteins – titer 1/80. DIF of the perilesional skin
revealed IgG1(+), IgG4(+) and C3(++) deposits along DEJ (Fig. 9D). Direct immunofluorescence
test on salt-split skin (ssDIF) showed IgG4(+) and C3 deposits on epidermal side of the split.
Aforementioned methods made it possible to diagnose BP and begin treatment with oral/
topical steroids, cyclophosphamide, doxycycline and antihistamines. Because of family history
of autoimmune blistering dermatosis coexistent with cancer, the patient was advised to
undergo meticulous follow-up to reveal any signs of malignancy as soon as possible.
6.2.3. Case 10 — Mucous membrane pemphigoid / hodgkin lymphoma
An elderly female, with swollen left supraclavicular lymph nodes, weight loss, fatigue, low
grade fever and night sweats, was admitted to internal diseases ward for diagnostics. Both
clinical symptoms, laboratory tests and histological examination of lymph node supported the
diagnosis of Hodgkin lymphoma (IIB). She was treated with ABVD chemotherapy regimen
(adriamycin, bleomycin, vinblastine, dacarbazine) and COPP regimen (cyclophosphamide,
vincristin, procarbazine, prednisone) - due to bad tolerance of anthracyclines, achieving
lymphoma remission.
Six years later, she called ENT professional due to dysphagia, oral itching and numerous
painfull erosions on oral mucosa covered with whitish coating (Fig. 10A). The lesions were
diagnosed mycologically as oral candidiasis (Candida famata, Candida glabrata). Antimyco‐
logical treatment seemed ineffective and another erosive lesion (3 cm in diameter) appeared
in umbilical region (Fig. 10B). She was directed to dermatological ward for further diagnostics
and treatment six months later. Her medical history was also significant for total hysterectomy
and episode of upper gastrointestinal bleeding (diffused intestinal metaplasia of the stomach
mucosa; coagulated). Laboratory blood tests showed increased sedimentation rate and CRP.
IIF on monkey esophagus did not revealed circulating IgG antibodies against desmosomal
proteins of keratinocytes and basement membrane antigens (Fig. 10C). DIF of the perilesional
skin from the umbilical region showed linear deposits of IgG(+/-), IgG1(+), and C3(+) along
dermal-epidermal junction (Fig. 10D). In natural blister, autoantibody deposits were seen on
epidermal side of the split. The diagnosis of MMP was based on clinical and DIF findings
fulfilling the criteria of this dermatosis.




Figure 8. A. Blisters and their evolutionary lesions on inflamed skin around colostomy. B. A part of neoplastic infiltrate
in the wall of large intestine showing cramped glandular ducts with irregular shapes. Epithelium cells with high-grade
atypical cells. Inflammation of the periphery. H+E staining. Courtesy of I. Turczuk-Bierła MD. C. Histology of perilesional
skin: Subepidermal vesicle with admixture of eosinophils within it. H+E staining. D. DIF of the blister skin margin: linear
IgG4(++) deposits along DEJ.
Figure 9. A. Erosions and bullae on erythematous skin forming “string of beans”. B. Group of small blisters forming
“cluster of jewels”. C. Immunohistochemical study of the lesional skin. Visualization of neutrophil elastase (NE) depos‐
its in the subepidermal blister. D. DIF on the perilesional skin: linear IgG4(+) deposits along DEJ.
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Figure 10. A. Mucosal erosions in oral cavity. B. Erosion in the navel. C. IIF study revealing no IgG antibodies binding
either desmosomal proteins of keratinocytes or basement membrane antigens. D. DIF of the perilesional navel skin:
linear IgG1(+) deposits alongside DEJ. Autoantibody deposits on epidermal side.
6.2.4. Case 11 — Bullous pemphigoid / renal cancer / prostate cancer
An elderly man visited the dermatologist due to disseminated erythematous itchy lesions,
papules, erosions and a few well-tensed blisters filled with serous exudate on the forearms,
arms and trunk (Fig. 11A, B). He was treated without clinical effect with antibiotics, antihist‐
amine drugs and oral steroids. After a month, he was directed to dermatological ward for
further diagnostics.
His medical history was significant for nephrectomy because of carcinoma clarocellulare,
prostate adenocarcinoma (Gleason 1+3=4) treated with brachytherapy (HDR; 20 Gy) and
radiotherapy, two hypermetabolic abdominal foci at level of kidney vessels in PET (suppos‐
edly metastatic lymph nodes), thyroid nodule and testis hydrocele. Laboratory tests revealed
increased CRP levels, monocytosis, eosinocytosis, hypertriglyceridemia.
Histology of the perilesional skin showed subepidermal blistering and inflammatory mixed
infiltrate with neutrophils and eosinophils (Fig. 11C). DIF of the perilesional skin of gluteal
region showed linear deposits of IgG1(+),  IgG4(++) and C3(+) along DEJ.  DIF performed
on vesicle  margin skin  showed linear  deposits  of  IgG(+),  IgG1(+),  IgG4(+++)  and C3(++)
along dermal-epidermal junction. (Fig.  11D).  IIF on monkey esophagus did not revealed
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circulating  IgG  antibodies  against  desmosomal  proteins  of  keratinocytes  and  basement
membrane antigens.  ELISA test  revealed increased serum anti-BP230  IgG level  –  81.356
RU/ml (cut-off point 20 RU/ml),  yet circulating anti-BP180 IgG level was normal – 8.037
RU/ml  (cut-off  point  20  RU/ml).  Vesicular  and paraneoplastic  BP  was  confirmed at  the
molecular level.
Published in [220].
Figure 11. A. Erythemous/oedematous lesions and erosions on the back in patient with vesiculous form of BP. Sticking
plaster marks the site of biopsy. B. Vesicular lesions on posteriomedial surface of the left arm. C. Histology of subepi‐
dermal blister. Inflammatory mixed infiltrate with neutrophils and eosinophils. H+E staining. D. DIF on perilesional
skin: IgG4 deposits along DEJ.
6.2.5. Case 12 — Bullous pemphigoid / lung cancer
A middle-aged heavy smoker visited dermatologist because of disseminated eruption of well-
tensed painful blisters (Fig. 12A). Histological examination was suggestive of BP (Fig. 12B).
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DIF of perilesional skin revealed linear deposits of IgG4(+) and C3(++) along dermal-epidermal
junction (Fig. 12C). IIF on monkey esophagus did not revealed circulating IgG antibodies
against either desmosomal proteins of keratinocytes or basement membrane antigens. The
patient was directed to dermatological ward for further diagnostics. Laboratory tests showed
leukocytosis, increased sedimentation rate and CRP. Apart of slightly increased CEA (6.79 ng/
ml; cut-off for non-smokers 5.00 ng/ml, for smokers 6.50 ng/ml), other cancer biomarkers (AFP,
CA19-9, Ca125, PSA) were negative. ELISA study was positive for serum anti-BP180 IgG –
19.50 RU/ml (cut-off point 9 RU/ml), yet negative for serum anti-BP230 IgG – 0.00 RU/ml (cut-
off point 9 RU/ml). The diagnosis of BP was established. Abdominal ultrasound displayed
enlarged liver without visible focal changes. Chest x-ray revealed a tumorous mass (7.0 cm x
6.6 cm), in middle lobe of the right lung, infiltrating lower root (Fig. 12D). Chest CT showed
heterogeneous tumor of the right lung with consequent emphysema and metastatic mediasti‐
nal lymph nodes.
Consulting pulmonologist ordered further diagnostics and treatment in pulmonological ward,
where bronchofiberoscopy was performed. With the histological diagnosis of carcinoma
planoepitheliale akeratodes (G3; T4N2M0; IIIB) the patient began chemotherapy (cisplatin/
vinorelbine regimen), yet he died within months.
Figure 12. A. Painful well-tensed blisters, crusts and erosions on erythematous skin of the axillary area. B. Histology:
subepidermal vesicle with abundant eosinophil infiltrate. H+E staining. C. DIF: linear deposits of IgG4 along DEJ. D.
Chest x-ray: solid mass in middle lobe of the right lung, Tumor infiltration of lower lung root.
Malignancy in Relation to Autoimmune Blistering Dermatoses: Molecular and Clinical Aspects
http://dx.doi.org/10.5772/55240
187
6.2.6. Case 13 — Bullous pemphigoid / prostate cancer
An elderly man consulted dermatology outpatient clinic due to itchy and painful well-tense
blisters on the legs and subsequently on flexural surfaces of the forearms dating back four
months (Fig. 13A). Perilesional skin bioptate and patient's blood sample were obtained for
diagnostic purposes. Histology showed subepidermal blister. Major basic protein was
visualized with immunohistochemical method marking eosinophil infiltrate (Fig. 13B). DIF
study revealed linear deposits of IgG1(+), IgG4(+) and C3(++) along DEJ (Fig. 13C). IIF on
monkey esophagus revealed circulating pemphigoid-type IgG, IgG1 and IgG4 antibodies
against basement membrane antigens, of titers respectively 1/320, 1/160 and 1/160 (Fig. 13D).
He was treated with limecycline, antihistamine drugs and incidental intramuscular steroids
and was directed to dermatological ward, with tentative diagnosis of BP, for further diagnos‐
tics and treatment.
On admission he presented oozing erosions and well-tensed blisters filled with serosangui‐
neous exudate on the right forearm. His medical history was significant for prostatic cancer
(treated for 8-year-period with hormonal therapy) and orchidectomy. He was treated by
urologist with tamsulosin, cyproterone, finasteride, flutamide, leuprorelin and goserelin.
Several months before lesions' appearance, the urologist ceased the hormonal treatment,
finding it purposeless. Laboratory tests revealed erythrocytopenia, increased sedimentation
rate and PSA (17.49 ng/ml; cut-off 4.00). Other cancer biomarkers (CEA, AFP), FOBT and stool
examination for parasite infestation were negative. ELISA test performed on patient's serum
and blister fluid showed increased anti-BP180 IgG level: 14.01 RU/ml and 13.21 RU/ml
respectively (cut-off 9 RU/ml) and increased anti-BP230 IgG level: 90.66 RU/ml and 75.85 RU/
ml respectively. The diagnosis of BP as a paraneoplastic syndrome was made. Due to previous
oncologic history, patient was urgently directed to urologist. Leuproreline readministration
with immunosuppressive and anti-inflammatory treatment enabled remission of cutaneous
lesions.
6.2.7. Case 14 — Ocular mucous membrane pemphigoid / endometrial cancer
A middle-aged woman was admitted to dermatological dispensary due to erosive lesions on
oral mucosa lasting for 2 years. She was treated by stomatologist, but without effect. Moreover,
due to involvement of conjunctivae two months earlier, she called the ophthalmologist, yet
the administered treatment seemed insufficient.
She was directed to dermatological ward for diagnostics. Her medical history was significant
for hysterectomy and adnexotomy with fistula and colon partial resection and transversosto‐
my due to endometrial adenocarcinoma infiltrating colon, causing recto-vaginal fistula (G2;
pT3aNx). She was planned for chemotherapy by gynaeco-oncologist. Her laboratory tests
showed increased sedimentation rate and increased antinuclear antibodies (ANA) titer. IIF on
monkey esophagus was negative for serum IgG autoantibodies against both desmosomal
proteins of keratinocyte and basement membrane antigens. DIF on oral mucous membrane
bioptate revealed scant linear C3 deposits along DEJ. Both clinical and immunopathological
findings supported the diagnosis of ocular MMP.
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6.2.8. Case 15 — Bullous pemphigoid / breast cancer
An elderly female with itchy bullous eruption on acral parts of the limbs visited the dermatolog‐
ical outpatient clinic. The lesions dated back four months and suggested BP. Her medical history
was significant for mastectomy due to breast cancer (infiltrating desmoplastic ductal and
intraductal carcinoma of intermediate grade of malignancy; G2 according to Bloom-Richard‐
son Grading System). DIF study of the perilesional skin sample revealed linear IgG4(+/-) and
C3(++) deposits along DEJ. IIF, on monkey esophagus as a substrate, revealed neither serum IgG
nor IgG4 antibodies against desmosomal proteins of keratinocytes and basement membrane
antigens. ELISA study defined serum anti-BP180 IgG level as >200 RU/ml (cut-off point 20 RU/
ml), yet serum anti-BP230 IgG level was normal – 3.182 RU/ml (cut-off point 20 RU/ml). With
molecular methods, the tentative clinical diagnosis of BP was confirmed. The patient re‐
mained in control of both dermatology and oncology outpatient clinics.
6.3. Discussion on MAABD cases
ABD can insidiously don the masks of other diseases imitating e.g. ulcerative carcinomas,
paronychia, eczema or pruritus. Generalized or localized, the eruption may remain disguised
for many months and years until the diagnosis is reached. In the light of contemporary data,
ABD circle shift in one patient by acquiring autoimmunity to new epitopes (via epitope spreading
or bystander effect) is possible. It should be concluded, that every circle is not a coherent group
of diseases, yet forms a continuum of autoimmune blistering dermatoses within autoimmune
Published in [21].
Figure 13. A. Blisters and their evolutionary lesions on urticarial skin on the flexural surface of a forearm. B. Eosinophil
major basic protein (MBP) deposits in lesional skin. Immunohistochemistry of subepidermal blister showing histologi‐
cal features of regeneration. C. DIF of perilesional skin: linear IgG1(+) deposits along DEJ. D. IIF on monkey esophagus:
IgG4 antibodies against epithelial basement membrane antigens.
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multiorgan syndrome. The causative relation between ABD and cancer is difficult to establish,
as both malignancy and ABD develops and stay undiagnosed over some time period.
In review based on PubMed, Scopus and EMBASE literature data, SCC has been found
responsible of projection the majority of paraneoplastic syndromes, with pemphigus being
one of the commonest dermatological conditions among them [194]. Case 1 and 2 both
presented carcinoma planoepitheliale/SCC with PV. The latter entity, by imitating mucosal
neoplastic process, presumably confused the clinicist and elongated the onset-diagnosis
period. Interestingly, both cases showed recrudescence of their pemphigus lesions after
radiotherapy. It seems to be a common finding in ABD, thus supports the role of radiotrauma-
induced denudation of formerly hidden epitopes in disease pathogenesis. The issue of SCC
driving autoimmunity is still enigmatic, yet change in DSG profile promoting tumor cell
migration may play a role in autoaggresion [177]. Similar cases to abovementioned ones were
reported in literature [17,195]. As pseudomyxoma peritonei classification still causes contro‐
versy [196], the association between PF and ovarian/appendiceal tumor in case 3 is disputable.
Some researchers speculated on the role of HPV16 and bacteria in development of this tumor
of appendiceal origin [197,198]. A single case of PNP, breast tumor and pseudomyxoma
peritonei was mentioned in literature [53]. To our best knowledge, case 3 is the first report on
coexistence of these two conditions. The concomitance of exophytic thoracic SCC-tumor and
PF (case 4) seem to be well-defined, yet behavior of the patient is difficult to comprehend since
his stinky tumor was present for years. Apparently, his PF lesions finally prompted him to
seek dermatological advise, but not the tumor itself. Apart of that, the case 5 is no less
enigmatic. PV may imitate multiple conditions and it should be noted, that his lip lesion
(described correctly as SCC by general pathologist) coexisted at the same site with the lesion
of PV initially missed by general pathologist but diagnosed as such by cutaneous pathologist
by reevaluation of initial specimen. Both above cases are portrayal of suspicious association
of SCC preceding pemphigus, whereas case 5 features additionally shifting PV phenotype,
supposedly because of active long-term pathological autoimmunization syndrome involving
epitope spreading phenomenon. Case 5 was mentioned in literature [190]. CA19-9 marker is
tumor-associated, but not tumor-specific marker. It is used as a screening test for gastrointes‐
tinal adenocarcinomas (colorectal, hepatic, lung, ovarian carcinoma and few non-malignant
conditions), first of all for pancreatic cancer [199]. Association of PV with breast cancer (case
6) or potential gastrointestinal tract adenocarcinoma is disputable. The case may be considered
a model for post-cancer ABD eruption and stands as an evidence for strong need of regular
screening for malignancy in ABD patients. As far as case 7 is concerned, once again we find it
questionable whether excised nasal/labial tumor was assessed properly as a cancerous or was
it just a limited exophytic lesion heralding PF – chancre of pemphigus [200]. There is limited
data concerning SCC, second commonest skin cancer coexistent with PF [201]. The negative
correlation between DSG1 expression and degree of dysplasia in SCC is an interesting issue
indicating contribution of desmosomal adhesion glycoproteins in cancerogenesis [202].
BP tends to manifest in natural and iatrogenic orifices featured by transient epithelium (e.g.
iatrogenic – the scar or the stomy site) (case 8). It seems coherent that malignant tumor causing
pathological immunization triggered the onset of BP. It was suggested that BP may be
Highlights in Skin Cancer190
secondary to surgical procedures exposing sequestered antigens of colon mucosa (particularly
BP180) [185,203–206]. The case is a hallmark of literature data [191–193]. As pemphigus and
pemphigoid may occur as a paraneoplastic syndrome accompanying malignant tumor, it
might be reasonable to form an online national registry of patients with ABD. Case 9 was
included to visualize that need. Although both ABD may not contain “paraneoplastic”
attribute, it is highly advisable to monitor all the patients with all ABD as group of high risk
of developing malignancy [16]. There is scant data on coexistence of MMP and Hodgkin
lymphoma (case 10) [207,208]. Moreover, the association between pemphigoid and non-
Hodgkin lymphoma may seem to be better exemplified [19,209,210]. Nonetheless, each
malignant lymphoproliferation may lead to impairment of immunological mechanisms via
the change of antigen suit, cytokine production, distorted antibody production and abnormal
cytokine production affecting many molecular pathways, both known and unknown. As far
as case 11 is concerned, practising dermatologist, perhaps suspecting Cottini form of DH,
obtained skin sample for DIF from lesion-free gluteal region (Fig. 11A). However, that area
should be regarded as non-optimal for diagnosing that form of DH with DIF [211]. Luckily,
BP-indicative deposits of immunoreactants were present at both lesion-free and perilesional
sites. The link between malignancy and pemphigoid in case 11 may be multi-sided. Both renal
and prostate cancer might be suspicious of contribution to autoaggression
[23,67,71,180,212,213] and the role of radiotherapy should not be considered irrelevant. Renal
cancer elicits paraneoplastic syndromes in 40% of patients, although dermatological manifes‐
tations seem to be extremely rare [70]. Cancerous lung involvement in BP (as in case 12) was
previously reported [34], yet pulmonary cancer seems to be more PV-associated. The cessation
of hormonal treatment seemed to trigger BP as a symptom of recurrence of prostate malignancy
(case 13) [21]. BP and prostate adenocarcinoma might be interrelated by BP180 issue. It was
observed, that prostatic malignant tumors may lack of hemidesmosomal structures – BP180
and less commonly BP230 [180]. Abnormal composition of detectable basement membrane
antigens participating in multiple molecular pathways may disbalance mechanisms of self-
tolerance consequently stimulating the pathological autoimmunity. Induction of pemphigoid
by trauma (in case 14 – by hysterectomy with partial colon resection), as reported in literature
[214], may seem a reasonable explanation. There is one similar report on anti-laminin-332 MMP
presumably associated with endometrial carcinoma [215]. BP in case 15 may be regarded
secondary to breast cancer. It may be possible, that the distortion of cell cohesion in neoplastic
cells leads to exposing normally hidden antigens or new epitopes are recognized by the
immunocompetent cells. There are reports mentioning overlapped breast cancer and BP
[20,84] as well as reports describing the evoking of autoimmune blistering dermatosis after
breast radiotherapy [216–218], that may change antigenicity of the malignant cells.
Cancer research gives molecular evidence for tumor genetic instability. Vast array of unique
tumor-specific neoantigens are presented on tumor's MHC molecules. Their recognition by T-
cells could induce anti-tumor immunity [219]. Antibody-assisted defense against tumor may
explain the fact of spontaneous cancer remissions. The other side of the coin may be the
autoimmunity caused by unspecific tumor antigens, that are displayed in many tissues being
easily accessible for T-cells. Hypothetically, some ABD might be really MAABD with tumor
eradicated in early phase.




The diversity of ABD results from diversity of recognizable epitopes of adhesive, desmosomal,
hemidesmosomal and basement membrane antigens that interact playing complicated role in
securing tissue integrity, intercellular communication and skin growth. Aberrant adhesive
molecule expression via epitope spreading, bystander effect and various signaling pathways,
may contribute to increased risk of developing cancer and its further prognosis. The altered
expression of adhesion complex molecules is thought to be vital for carcinoma motility and
invasion. The conjunction of malignancy and ABD phenomenon still remains an area of interest
of researchers worldwide, as it may benefit in development of more specific diagnostic tests
and precise therapeutic strategies.
Concomitance of malignancy and these serious clinical conditions may dramatically decrease
the patient survivorship. The wise clinician ought to trace potential malignancy in each and
every one of the patients with ABD, regardless of deceptive lack of "paraneoplastic" epithet in
the currently used misleading nosology for majority of those dermatoses, as such an associa‐
tion between those two groups of entities, was demonstrated not to be rare. Therefore, the
diagnosis of ABD should be followed not only by screening, but also monitoring/periodical
checking for malignancies. Moreover, the replacement of indiscriminate immunosuppressive
therapy by individualized targeted therapy should be recommended. There is burning need
for awareness of such coexistence also among oncologic patients, as ADB may herald the
recurrence of malignancy.
Author details
Paweł Pietkiewicz, Justyna Gornowicz-Porowska, Monika Bowszyc-Dmochowska and
Marian Dmochowski
*Address all correspondence to: mkdmoch@wp.pl
Cutaneous Histopathology and Immunopathology Section, Department of Dermatology,
Poznan University of Medical Sciences, Poznań, Poland
We dedicate this work to our patients suffering from malignancy concomitant with autoim‐
mune blistering dermatosis
References
[1] Dmochowski M. Autoimmunizacyjne dermatozy pecherzowe. Poznań: Wydawnict‐
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